2021 / 02

Next Paper
DOI: 10.24075/brsmu.2021.011

OPINION

Compulsory licensing in pharmaceutical industry: current state of affairs and prospects

Gaydin TY1,2, Rozhnova SA1
About authors

1 Pirogov Russian National Research Medical University, Moscow, Russia

2 Lomonosov Moscow State University, Moscow, Russia

Correspondence should be addressed: Timofey Yu. Gaydin
Ostrovityanova, 1, Moscow, 117997; ur.usm.noce@a81ytag

About paper

Author contribution: Gaydin TY analyzed the literature, conducted the study and wrote the draft of the manuscript; Rozhnova SA planned and conducted the study, analyzed the literature and wrote the draft of the manuscript

Received: 2021-02-09 Accepted: 2021-02-22 Published online: 2021-03-09
|
  1. Grazhdanskij kodeks Rossijskoj Federacii. 4 chast'. Available from: https://base.garant.ru/10164072/. Russian.
  2. Romasanta A, van der Sijde P, van Muijlwijk-Koezen J. Innovation in pharmaceutical R&D: mapping the research landscape. Scientometrics. 2020. 125 (3): 1801–32. DOI: 10.1007/s11192020-03707-y.
  3. Rozhnova SA, Cypkina AV. Analiz sistemy organizacii farmacevticheskoj razrabotki lekarstvennyh sredstv. Razrabotka i registracija lekarstvennyh sredstv. 2017; 3 (20): 170–178. Russian.
  4. Zakonoproekt # 842633-7 «O vnesenii izmenenija v stat'ju 1360 Grazhdanskogo kodeksa Rossijskoj Federacii». Available from: https://sozd.duma.gov.ru/bill/842633-7. Russian.
  5. Reshenie ot 08.06.2018 Arbitrazhnogo suda goroda Moskvy po delu # A40-71471/17-110-675. Available from: https://kad.arbitr. ru/Card/322413fa-38a7-4085-9cc7-3c8ff9fd7d92. Russian.
  6. Postanovlenie Suda po intellektual'nym pravam ot 27.12.2018 # S01-1064/2018 po delu # A40-71471/2017. Russian.
  7. Scopel C. Chaves G. Initiatives to challenge patent barriers and their relationship with the price of medicines procured by the Brazilian Unified National Health System. Cadernos de Saúde Pública. 2016. 32 (11): 1–11. DOI: 10.1590/0102-311X00113815.
  8. Rodrigues W, Soler O. Licença compulsória do efavirenz no Brasil em 2007: contextualização. Revista Panamericana de Salud Pública. 2009; 26 (6): 553–559.
  9. Burki T. Indian government awards compulsory licence for sorafenib. The Lancet Oncology. 2012; 13 (4): p.e146. DOI: 10.1016/S1470-2045(12)70108-0.
  10. Steele JW. Generic Competition in Canada. PharmacoEconomics. 1994; 6 (5): 480–482. DOI:10.2165/00019053-199406050-00010.
  11. Gosudarstvennyj reestr predel'nyh otpusknyh cen. Available from: http://grls.rosminzdrav.ru/PriceLims.aspx. Russian.
  12. Mihailova OP. Metody marketingovoĭ diagnostiki vneshneĭ ̆ sredy promyshlennogo predprijatija v konture strategicheskogo upravlenija. Bjulleten' Orenburgskogo nauchnogo centra UrO RAN. 2015; 3: 1–12. Russian.
  13. Gaiduk VI, Takaho YeE. Metody i instrumenty strategicheskogo ̆ planirovanija. Nauchnyi zhurnal KubGAU. 2014; 103 (09): 1–18. ̆ Russian.
  14. Federal'nyj zakon «Ob obrashhenii lekarstvennyh sredstv» ot 12.04.2010. Available from: http://www.consultant.ru/document/ cons_doc_LAW_99350/. Russian.
  15. Shastitko AE, Kurdin AA. Stimuly k processnym innovacijam v diskretnyh strukturnyh al'ternativah konkurentnoj politiki. Voprosy jekonomiki. 2016; (4): 56–85. DOI: 10.32609/0042-8736-20164-56-85. Russian.
  16. Goto A. Innovation and Competition Policy. JER. 2009; 60: 55–62. DOI: 10.1111/j.1468-5876.2008.00466.x.
  17. Federico G, Scott Morton F, Shapiro C. Antitrust and Innovation: Welcoming and Protecting Disruption. Innovation Policy and the Economy. 2020; 20: 125–190. DOI: 10.1086/705642.
  18. Seifert J. Welfare effects of compulsory licensing. J Regul Econ. 2015; 48: 317–350. DOI: 10.1007/s11149-015-9288-9.
  19. Bond E, Saggi K. Compulsory licensing, price controls, and access to patented foreign products. Journal Of Development Economics. 2014; 109: 217–228. DOI: 10.1016/j.jdeveco.2014.04.001.
  20. Moser P, Voena A. Compulsory Licensing: Evidence from the Trading with the Enemy Act. American Economic Review. 2012; 102: 396–427. DOI: 10.1257/aer.102.1.396.
  21. Sarmah A, De Giovanni D, De Giovanni P. Compulsory licenses in the pharmaceutical industry: Pricing and R&D strategies. European Journal of Operational Research. 2020; 282 (3): 1053– 69. DOI: 10.1016/j.ejor.2019.10.021.
  22. Gbadegeshin SA. The Effect of Digitalization on the Commercialization Process of High-Technology Companies in the Life Sciences Industry. Technology Innovation Management Review. 2019; 9 (1): 49–63. DOI: 10.22215/timreview/1211.
  23. Acemoglu D, Akcigit U. Intellectual Property Rights Policy, Competition and Innovation. Journal of the European Economic Association. 2012; 10 (1): 1–42. DOI: 10.1111/j.15424774.2011.01053.x.
  24. Abbott F, Reichman J. Facilitating Access to Cross-Border Supplies of Patented Pharmaceuticals: The Case of the COVID-19 Pandemic. Journal Of International Economic Law. 2020; 23 (3): 535–561. DOI: 10.1093/jiel/jgaa022.